Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV- associated diseases

Journal of Infectious Diseases

Volumn 179, Issue 5, 1999, Pages 1108-1115

  Meij, Pauline ^a,b   Vervoort, Marcel B H J ^a,b   Aarbiou, Jamil ^a,b,c   Van Dissel, Paul ^a,b,d   Brink, Arjen ^a,b   Bloemena, Elisabeth ^a,b   Meijer, Chris J L M ^a,b   Middeldorp, Jaap M ^a,b,e  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Bioscience Research Unit   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e Organon Teknika   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LATENT MEMBRANE PROTEIN 1; SYNTHETIC PEPTIDE; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; INFECTIOUS MONONUCLEOSIS; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; VIRUS CARRIER; VIRUS INFECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BURKITT LYMPHOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOBLOTTING; INFECTIOUS MONONUCLEOSIS; LYMPHOMA; MICE; MOLECULAR SEQUENCE DATA; NASOPHARYNGEAL NEOPLASMS; PEPTIDES; RECOMBINANT PROTEINS; VIRAL MATRIX PROTEINS;

EID: 0032968793     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314704     Document Type: Article

References (43)

1. 1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields virology. 3rd ed. Vol 2. Philadelphia: Lippincott-Raven, 1996:2397-446.
2. 2. Zur-Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinoma of the nasopharynx. Nature 1970;228:1056-8.
3. 3. Wolf H, Zur-Hausen H, Becker V. EB víral genomes in epithelial nasopharyngeal carcinoma cells. Nature 1973;244:245-7.
4. 4. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 1993;99:265-76.
5. 5. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, et al. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 1991;138:149-63.
6. + malignant lymphomas. Crit Rev Oncogenesis 1993;4:191-239.
7. 7. Pallesen G, Hamilton-Dutoit SJ, Zhou X. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. Adv Cancer Res 1993;62:179-239.
8. 8. De Bruin PC, Jiwa NM, Oudejans JJ, et al. Presence of Epstein-Barr virus in extranodal T-cell lymphormas: differences in relation to site. Blood 1994;83:1612-8.
9. 9. Kanavaros P, Brière J, Lescs MC, Gaulard P. Epstein-Barr virus in non-Hodgkin's lymphomas of the upper respiratory tract: association with sinonasal localisation and expression of NK and/or T-cell antigen by tumour cells. J Pathol 1996;178:297-302.
10. 10. Matsunou H, Konishi F, Hori H, et al. Characteristics of Epstein-Barr virus-associated gastric carcinoma with lymphoid stroma in Japan. Cancer 1996;77:1998-2004.
11. 11. Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev 1991;4:129-35.
12. 12. Wolf H, Bogedain C, Schwarzmann F. Epstein-Barr virus and its interaction with the host. Intervirology 1993;35:26-39.
13. 13. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 1987;6:2743-51.
14. 14. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1 and LMP2 transcripts. J Virol 1992;66:2689-97.
15. 15. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;337:320-2.
16. 16. Hamilton-Dutoit SJ, Pallesen G. A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. Am J Pathol 1992;140:1315-25.
17. 17. Hummel M, Anagnostopoulus J, Korbjuhn P, Stein H. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low-and high-grade types. J Path 1995; 175:263-71.
18. 18. Oudejans JJ, Jiwa NM, van den Brule AJC, et al. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 1995;147:923-33.
19. 19. Brooks LA, Lear AL, Young LS, Rickinson AB. Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol 1993;67:3182-90.
20. 20. Rowe M, Finke J, Szigeti R, Klein G. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol 1988;69:1217-28.
21. 21. Levitskaya J, Coram M, Levitsky V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-8.
22. 22. Rickinson AB, Murray RJ, Brooks J, Griffin H, Moss DJ, Masucci MG. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv 1992;13:53-80.
23. 23. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus associated diseases. Microbiol Rev 1995;59:387-405.
24. 24. Sulitzeanu D, Szigeti R, Hatzubai A, et al. Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP). Immunol Lett 1988;18:301-6.
25. 25. Modrow S, Wolf H. Characterization of two related Epstein-Barr virus encoded membrane proteins that are differentially expressed in Burkitt lymphoma and in vitro transformed cell lines. Proc Natl Acad Sci USA 1986;83:5703-7.
26. 26. Chen HF, Kevan-Jah S, Suentzenich KO, Grässer FA, Mueller-Lantzsch N. Expression of the Epstein-Barr virus latent membrane protein (LMP) in insect cells and detection of antibodies in human sera against this protein. Virology 1992;190:106-15.
27. 27. Lennette ET, Winberg G, Yadav M, Enblad G, Klein G. Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer 1995:31A: 1875-8.
28. 28. Frech B, Zimber-Strobl U, Yip TTC, Lau WH, Mueller-Lantzsch N. Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. J Gen Virol 1993;74:811-8.
29. 29. Thorley-Lawson DA, Israelsohn ES. Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus encoded p63/latent membrane protein. Proc Natl Acad Sci USA 1987;84:5384-8.
30. 30. Sing AP, Ambinder RF, Hong DJ, et al. Isolation of Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV Hodgkin's disease. Blood 1997;89:1978-86.
31. 31. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (EMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998;28:451-8.
32. 32. Rowe M, Khanna R, Jacob CA, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1 : coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995;25:1374-84.
33. 33. Wang S, Rowe M, Lundgren E. Expression of the Epstein Barr virus transforming protein LMP1 causes rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1996;56:4610-3.
34. 34. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 1994; 57:240-4.
35. 35. Middeldorp JM, Herbrink P. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J Virol Methods 1988; 21:133-46.
36. 36. Van Grunsven WMJ, Nabbe A, Middeldorp JM. Identification and molecular characterization of two diagnostically relevant marker proteins of Epstein-Barr virus capsid antigen complex. J Med Virol 1993,40:161-9.
37. 37. Jiwa NM, Oudejans JJ, Dukers DF, et al. Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases. J Clin Path 1995;48:438-42.
38. 38. Middeldorp JM, Meloen RH. Epitope-mapping on the Epstein-Barr virus major capsid protein using systematic synthesis of overlapping oligopeptides. J Virol Methods 1988;21:147-59.
39. 39. Van Grunsven WMJ, Spaan WJM, Middeldorp JM. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J Infect Dis 1994;170:13-9.
40. 40. Middeldorp JM. Epstein-Barr virus peptide and combinations thereof. AKZO Nobel: European patent application no. 9302478, 14 September 1993.
41. 41. Middeldorp JM. Epstein-Barr virus peptides and antibodies against these peptides. Akzo Nobel: European patent application no. 95201486.8, 6 June 1995.
42. 42. Gratama JW, Ernberg I. Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res 1995;67:197-225.
43. 43. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994;68:7374-85.